RT Journal Article
SR Electronic
T1 COVID-19 prevalence in 161 countries and over time
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.01.20241539
DO 10.1101/2020.12.01.20241539
A1 Stilianos Louca
YR 2020
UL http://medrxiv.org/content/early/2020/12/02/2020.12.01.20241539.abstract
AB Effectively evaluating, controlling and predicting the course of the COVID-19 pandemic requires knowledge of the true number of infections in the population. This number, however, generally differs substantially from the number of confirmed cases due to a large fraction of asymptomatic infections as well as geographically and temporally variable testing effort and strategies. Here I use age-stratified death count statistics, published age-dependent infection fatality risks and stochastic modeling to estimate the true prevalence and growth of COVID-19 infections among adults (age ≥ 20 years) in 161 countries, from early 2020 until November 1, 2020. My predictions are largely consistent with data from multiple previous nationwide seroprevalence surveys. As of November 1, 2020, the nationwide cumulative COVID-19 prevalence (past and current infections relative to the population size) is estimated at 31% (95%-CI 22-50) for Peru, 27% (17–41) for Mexico, 22% (14–34) for Brazil, 12% (7.2-20) for the US, 11% (6.4–18) for the United Kingdom, 8.2% (5.2–15) for France, 7.4% (4.9–13) for Sweden, 4.2% (2.5–6.8) for Canada, 1.8% (1.2–3) for Germany and 0.12% (0.074–0.26) for Japan. These time-resolved estimates expand the possibilities to evaluate the factors influencing the pandemic’s progression and to assess vaccination needs around the world. Periodically updated estimates are available at: www.loucalab.com/archive/COVID19prevalenceCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a US National Science Foundation RAPID grant #2028986.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/A.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this manuscript were obtained from publicly accessible sources. https://covid19.who.int/table https://population.un.org/wpp/Download/Standard/CSV https://osf.io/7tnfh